The Efficacy of Sertraline, Escitalopram, and Nicergoline in the Treatment of Depression and Apathy in Alzheimer’s Disease: The Okayama Depression and Apathy Project (ODAP)

Takemoto, Mami; Ohta, Yasuyuki; Hishikawa, Nozomi; Yamashita, Toru; Nomura, Emi; Tsunoda, Keiichiro; Sasaki, Ryo; Tadokoro, Koh; Matsumoto, Namiko; Omote, Yoshio; Abe, Kōji

doi:10.3233/jad-200247

Cited by 12 publications

(12 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Sertraline was the most frequently investigated substance (within seven trials), followed by citalopram/escitalopram (within four trials) (Table 1). Although we specifically focused on randomized controlled trials in patients with Alzheimer’s disease, a few trials (Roth et al , 1996; Katona et al , 1998; de Vasconcelos Cunha et al , 2007; Bergh et al , 2012) did not exactly specify the causes of dementia among their participants, included patients with mild cognitive impairment (Roth et al , 1996) or compared different antidepressants without a placebo group (Katona et al , 1998; Mokhber et al , 2014; Takemoto et al , 2020). In contrast to others (He et al , 2021), we did not include clinical trials not available through PubMed.…”

Section: Literature Search Results and Study Selection Limitationsmentioning

confidence: 99%

“…Takemoto et al (2020) also did not establish a placebo group when comparing sertraline with escitalopram and nicergoline. Whereas escitalopram (average dose 7.3 mg/day) was associated with an antidepressant effect in the geriatric depression scale (Yesavage et al , 1982), sertraline (average dose 31.8 mg/day) primarily improved apathy (Takemoto et al , 2020).…”

Section: Selective Serotonin Reuptake Inhibitorsmentioning

confidence: 99%

“…Utilizing the Cornell Scale for Depression in Dementia (Alexopoulos et al , 1988), the authors recommend that future studies should focus on a subgroup of patients with severe depression (An et al , 2017). In a smaller trial (Takemoto et al , 2020), escitalopram (average dose 7.3 mg/day) but not sertraline (average dose 31.8 mg/day) was associated with antidepressant effect in patients with Alzheimer’s disease, and a high score on the Geriatric Depression Scale (Yesavage et al , 1982).…”

Section: Selective Serotonin Reuptake Inhibitorsmentioning

confidence: 99%

“…Mokhber et al (2014) showed superior effectiveness of sertraline (maximum dose 150 mg/day) in 59 patients with moderate Alzheimer’s disease when compared with venlafaxine and desipramine (maximum doses 150 mg/day) in symptoms of depression, cognitive and behavioral measures using screening tests (Hamilton, 1960; Mahoney and Barthel, 1965; Folstein et al , 1975). Takemoto et al (2020) also did not establish a placebo group when comparing sertraline with escitalopram and nicergoline. Whereas escitalopram (average dose 7.3 mg/day) was associated with an antidepressant effect in the geriatric depression scale (Yesavage et al , 1982), sertraline (average dose 31.8 mg/day) primarily improved apathy (Takemoto et al , 2020).…”

Section: Selective Serotonin Reuptake Inhibitorsmentioning

confidence: 99%

See 3 more Smart Citations

Pharmacologic treatment of depression in Alzheimer’s disease

Haußmann

Donix

2022

International Clinical Psychopharmacology

View full text Add to dashboard Cite

Major depressive disorder and Alzheimer’s disease are common among older people, frequently co-occur and severely impact the quality of life. Unfortunately, data on the efficacy of pharmacologic treatment of depressive symptoms in patients with the neurodegenerative disease remain inconclusive. The heterogeneity of treatment study designs, from varying diagnostic specificity to diverse outcome measures, contributes to conflicting evidence across single trials and meta-analyses. In this literature review, we focus on commercially available products for antidepressant treatment in demented individuals and show how insights from randomized controlled trials could still guide and be aligned with common clinical practice.

show abstract

Section: Literature Search Results and Study Selection Limitationsmentioning

confidence: 99%

Section: Selective Serotonin Reuptake Inhibitorsmentioning

confidence: 99%

Section: Selective Serotonin Reuptake Inhibitorsmentioning

confidence: 99%

Section: Selective Serotonin Reuptake Inhibitorsmentioning

confidence: 99%

See 2 more Smart Citations

Pharmacologic treatment of depression in Alzheimer’s disease

Haußmann

Donix

2022

International Clinical Psychopharmacology

View full text Add to dashboard Cite

show abstract

“…Subse-quent reviews concluded that methylphenidate’s effect was small but significant, though it should be weighed against its significant side effects including high blood pressure, cough and osteoarticular pain [ 46 ]. In the Okayama Depression and Apathy Project, patients receiving escitalopram showed significant improvement in GDS score in Alzheimer’s whereas patients receiving sertraline showed improvement in the Apathy Scale [ 49 ].…”

Section: Management Of Apathymentioning

confidence: 99%

Apathy: Neurobiology, Assessment and Treatment

Fahed

Steffens

2021

Clin Psychopharmacol Neurosci

View full text Add to dashboard Cite

Apathy is a highly prevalent, disabling and treatment resistant syndrome. It is defined as a quantitative reduction of goal- directed activity in comparison to the patient’s previous level of in multiple dimensions including behavior/cognition, emotion and social interaction. It has been described in major depressive disorder, Alzheimer’s disease, frontotemporal dementia, Parkinson’s Disease, cerebrovascular disease, and vascular dementia, among others. This review will address the neuropsychology and associated neurobiological underpinnings of apathy in the above conditions, identify specific methods to assess apathy clinically, and review the literature on managing apathy across these various disorders.

show abstract

Prevalence, treatment, and neural correlates of apathy in different forms of dementia: a narrative review

Parrotta,

Cacciatore,

D’Andrea

et al. 2023

Neurol Sci

View full text Add to dashboard Cite

Objectives The aim of this review is to provide an overview on prevalence and clinical tools for the diagnosis of apathy, as well as on neurophysiological and neuroimaging findings obtained from studies in patients with apathy in different forms of dementia, including Alzheimer’s disease (AD), vascular (VaD) and mixed dementia, frontotemporal dementia (FTD), and Parkinson’s disease dementia (PDD). Methods Randomized controlled trials, non-randomized controlled trials, controlled before–after studies, and interrupted time series from four databases (WebOfScience, Scopus, Pubmed, and PsycINFO) addressing apathy in adults or older people aged over 65 years of age affected by dementia were included. Results The prevalence of apathy was 26–82% for AD, 28.6–91.7 for VaD, 29–97.5% in PDD, and 54.8–88.0 in FTD. The assessment of apathy was not consistent in the reviewed studies. Methylphenidate was the most successful pharmacological treatment for apathy. Neurobiological studies highlighted the relationship between both structural and functional brain areas and the presence or severity of apathy. Conclusion Apathy is a very common disorder in all types of dementia, although it is often underdiagnosed and undertreated. Further studies are needed to investigate its diagnosis and management. A consensus on the different evaluation scales should be achieved.

show abstract

The Efficacy of Sertraline, Escitalopram, and Nicergoline in the Treatment of Depression and Apathy in Alzheimer’s Disease: The Okayama Depression and Apathy Project (ODAP)

Cited by 12 publications

References 17 publications

Pharmacologic treatment of depression in Alzheimer’s disease

Pharmacologic treatment of depression in Alzheimer’s disease

Apathy: Neurobiology, Assessment and Treatment

Prevalence, treatment, and neural correlates of apathy in different forms of dementia: a narrative review

Contact Info

Product

Resources

About